Patient P-02670

Synthetic patientMETA-24 · Day 153 · 45–54 · F · baseline S14Open companion preview

Therapy response

Declining

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 75 SC-12 recommended — Supportive Compound SC-12
Day 76 Patient accepted — Started SC-12 in the companion
Day 82 GI symptom burden −24% vs expected — Supportive Compound SC-12
Day 88 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 69.

Primary contributors, last 14 days

Nutritional resilience-7
GI instability+4
Treatment adherence-4
Inflammatory activity-3
Toxicity-2

What helped?

Supportive Compound SC-12Day 75
Result: symptom burden −24%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
89% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- WearableSleep 5.6 h, below personal baseline
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 73 bpm
- Wearable300 steps/day
- WearableShort sleep window
Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 58
Drug metabolism and exposure ↑20
- BloodToxicity index 46

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.3 · butyrate capacity 44/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 49 ms
Sleep: 5.7 h
Steps: 897
Resting HR: 73 bpm

Daily log: GI score 59, nutritional resilience 37, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02535	61%	S14	SC-12	improved	50
P-02234	56%	S14	GI-04	improved	36
P-02348	56%	S14	GI-04	improved	49
P-02516	54%	S14	SC-12	improved	51
P-02253	52%	S14	NP-02	no change	41
P-02363	52%	S14	GI-04	improved	49
P-02559	52%	S18	SC-12	no change	48
P-02002	51%	S14	GI-04	improved	47
P-02018	51%	S01	GI-04	improved	46
P-02103	51%	S14	GI-04	improved	46
P-02310	51%	S14	GI-04	improved	35
P-02326	51%	S18	NP-02	improved	44